Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

12.91 +0.11 (+0.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atara Biotherapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Atara Biotherapeutics Provides Update on ATA2271 Autologous CAR T Trial
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Fujifilm To Buy Cell Therapy Plant From Atara For $100M
FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, will acquire a cell therapy plant from Atara Biotherapeutics Inc (NASDAQ: ATRA)  
Via Benzinga
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
Preview: Atara Biotherapeutics's Earnings
Atara Biotherapeutics (NASDAQ:ATRA) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept... 
Via FinancialNewsMedia
Atara Biotherapeutics Shares Fall After Reporting Patient Death In ATA2271 Autologous CAR T Trial
Memorial Sloan Kettering Cancer Center's (MSK) has notified the FDA of a fatal serious adverse event (SAE) associated with a patient in Phase 1 study of Atara... 
Via Benzinga
The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm
From Atara Biotherapeutics, Inc.
Via Business Wire
New Landmark Nature Study Provides Long-Sought Mechanistic Link Between EBV and Multiple Sclerosis, Extending Findings from Recent Paper in Science That Identified EBV as the Leading Cause of Multiple Sclerosis
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Be The Match BioTherapies® and Atara Biotherapeutics Announce Multi-Year Partnership Extension
From Be The Match BioTherapies
Via Business Wire
Atara Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Galera Therapeutics (NASDAQ:GRTX) stock increased by 134.05% to $3.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ: VACC) announced that... 
Via Benzinga
Atara Bio Unveils Pivotal Data On T Cell Therapy Tabelecleucel In Transplant Patients
Atara Biotherapeutics Inc (NASDAQ: ATRA) posted efficacy and safety results from its Phase 3 ALLELE study of tabelecleucel (tab-cel) for Epstein-Barr virus-positive... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! It's time to start off the day with a breakdown of the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers MIND Technology, Inc. (NASDAQ: MIND) rose 37.2% to $1.88 in pre-market trading after the company reported it entered into a Cooperative Research and Development Agreement... 
Via Benzinga
Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021
From Atara Biotherapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug... 
Via Benzinga
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
How Bad Are Atara Biotherapeutics's Earnings? | Return On Capital Employed
Atara Biotherapeutics (NASDAQ:ATRA) brought in sales totaling $5.37 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 0.96%, resulting in a... 
Via Benzinga
Atara Biotherapeutics, inc (ATRA) Q3 2021 Earnings Call Transcript
ATRA earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data
From Atara Biotherapeutics, Inc.
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.